Stoke Therapeutics Shares Plunge Following Clinical Trial Data Release

Q3 2025 Financial Outlook

Stoke Therapeutics equity faced substantial selling pressure as new clinical trial results triggered a sharp decline in its market value. The biopharmaceutical company’s stock dropped significantly as investors reassessed its prospects following the latest research updates.

Market participants are closely monitoring Stoke Therapeutics’ upcoming financial disclosure for the third quarter of 2025. Company leadership has scheduled a webcast and conference call for Tuesday, November 4, 2025, to review performance results covering the period through September 30, 2025.

Financial projections indicate:

• An anticipated loss of 57 cents per share
• Revenue growth of 12.6% to reach approximately $5.511 million
• Unchanged analyst estimates over the preceding three months